In order to assess the potential of interleukin 7 (IL-7) as an immunotherapeutic agent in human melanoma, we have evaluated the in vitro activity of IL-7-induced lymphokine-activated killer (LAK) cells from patients with advanced melanoma against allogeneic and autologous melanoma cells. Peripheral blood lymphocytes (PBLs) from 14 patients with stage III melanoma were isolated and incubated in the presence of 1,000 U ml-' IL-7 and 1 U ml-' IL-2 for comparison. LAK-ell activity was determined by a 24 h cytotoxicity assay using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. The activity of IL-7-induced LAK cells against two allogeneic melanoma cell lines was 32.7% (± 17.9) against SK-Mel-37 and 38.1% (± 12.5) against SK-Mel-23 at an effector-to-target (En ratio of 20:1. The activity of IL-2-induced LAK cells was significantly higher against SK-Mel-37 (78 ± 24.6%) and against SK-Mel-23 (73.5 ± 19.7%). IL-7 and suboptimal doses of IL-2 (10 U ml-I) were found to have a co-stimulatory on lymphocyte proliferation as well as on LAK activity. Against autologous melanoma cells, the activity of IL-7-and IL-2-induced LAK cells did not differ significantly (55.8 ± 25.6% versus 68.7 ± 21.7% respectively). In two patients, IL-7-induced LAK-cell activity against autologous melanoma cells exceeded even that of IL-2 significantly (67% vs 35% and 95% vs 82%). Levels of tumour necrosis factor a (TNF-x) in the supernatants of LAK-cell cultures generated by IL-7 were lower than those of IL-2-generated LAK-cell cultures. These results suggest that IL-7 is a potential alternative to immunotherapy with IL-2 in terms of efficacy and possible side-effects and encourages pilot studies with IL-7 in melanoma patients.
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Immunotherapy with IL-2 with or without LAK cells has achieved some impressive regressions in patients with advanced melanoma who had failed on conventional therapy (Rosenberg et al., 1985; Fletcher et al., 1987) . However, the clinical responses to this kind of therapy are infrequent and often transient (Rosenberg et al., 1989) . Furthermore, highdose imnunotherapy with IL-2 is associated with severe toxicity including pulmonary congestion, hypotension, oedema or anuria, known as the capillary leakage syndrome (Rosenstein et al., 1986; Kozeny et al., 1988) . These limitations of an initially promising kind of immunotherapy have led to an extensive search for better-tolerated treatment schedules as well as alternative agents in immunotherapy of human melanoma. IL-7 was originally described as a growth factor for early B cells (Namen et al., 1988) . Further characterization revealed that IL-7 is also an important differentiation factor for the maturation and proliferation of T lymphocytes (Chazen et al., 1989; Londei et al., 1990) . supports the development of cytotoxic T cells and generates LAK activity in human PBLs against Daudi cells (Alderson et al., 1990; St6tter & Lotze, 1991; St6tter et al., 1991) . Recent data indicate that the spectrum of cells responsive to IL-7 is broader than originally expected and includes monocytes (Alderson et al., 1991) and melanoma cells (Kirnbauer et al., 1992) . Therefore, IL-7 can be considered to be a multifunctional cytokine acting on various cell lineages. Most recently, human keratinocytes have been shown to secrete IL-7 (Sakimura et al., 1993) , suggesting an important immunoregulatory role of this cytokine for dendritic T cells with in the epidermal compartment (Matsue et al., 1993) . We have recently shown that melanoma cells from allogeneic melanoma cell lines can be lysed by IL-7-induced LAK cells from healthy donors (Schadendorf et al., 1994a induced LAK-cell activity. However, sparing of keratinocytes and endothelial cells predicts that LAK cells generated by IL-7 are more discriminative in their target cell spectrum than IL-2-induced LAK cells (Schadendorf et al., 1994a) . In order to address the question of whether patients with advanced malignant melanoma could benefit from immunotherapy with IL-7, we have examined the in vitro susceptibility of allogeneic as well as autologous melanoma cells to LAK cells (from 14 patients with metastatic melanoma) stimulated with IL-7 or IL-2. In addition, we have evaluated the comparative concentrations of TNF-a in the supernatants of LAK-ell cultures generated by IL-7 or IL-2 since secondarily induced cytokines such as TNF-x are thought to play a key role in the development of side-effects during immunotherapy with (Siegel & Puri. 1991) .
Material and methods

Cvtokines
Human recombinant IL-7 was provided by Immunex (Seattle, WA, USA) with a specific activity of 4.7 x 10' U mg-' and 3.9 endotoxin units per ng of protein. The specific activity was determined with a bioassay that employs the IL-7-dependent IxN/Lb pre-B-cell line (Namen et al., 1988) . Human recombinant IL-2 was purchased from Boehringer (Mannheim, Germany) and had a specific activity of 2 x 106 U mg-' and fewer than 100 endotoxin units per ng.
Cell culture of melanoma cell lines The human melanoma cell lines SK-Mel-37 and SK-Mel-23 were grown as previously described (Schadendorf et al., 1994b AGAINST MELANOMA 55 melanoma cells from tumour specimens from lymph nodes, cutis or subcutis were prepared as described previously (Schadendorf et al., 1994b) . For testing, passages 2-5 were used. Parallel cytospins of the tumour cells were done, and it was confirmed by immunocytochemistry that >95% were -100 positive.
LAK-cell generation from patients with melanoma Peripheral blood mononuclear cells (PBMCs) were obtained from 14 patients with stage III melanoma (age 32-89, equal sex ratio) by Ficoll-Hypaque centrifugation. Any form of chemotherapy, immunotherapy or hormone therapy had to be discontinued 6 weeks before blood collection. After removal of the adherent monocytes by incubating the PBMCs on plastic plates for 1 h at 37C, the PBLs were decanted and either cryopreserved or immediately processed for the generation of LAK cells (Grimm et al., 1982; Schadendorf et al., 1994b) . In short, PBLs were incubated at a density of 2 x 106 cells ml-' in RPMI-1640 supplemented with glutamine, fetal calf serum and antibiotics as mentioned above, and 1,000 U ml1' IL-7 or 100 U ml1' IL-2. One thousand units of IL-7 represents 0.1 mg and 100 U of IL-2 represents 0.033 mg. The cells were incubated in 25 cm2 flasks (Greiner, Frickenhausen, Germany) in an upright position for 4 days in 5% carbon dioxide at 3rC. On day 4, LAKcell concentration was determined by haemocytometer counts of cells excluding 0.18% trypan blue dye.
Ctotoxicitiv assay LAK-cell activity was determined with a 24 h tetrazoliumbased colorimetric assay originally described by Mosman (1983) . The measured absorbance is proportional to the number of viable cells. Modified as a cytotoxicity assay for the quantification of anti-tumour effects mediated by LAK cells, this test has been found to compare favourably with the 5'Cr-release assay in terms of sensitivity and reproducibility, particularly if long-term cytotoxicity is to be measured (Heo et al., 1990 
Statistical analysis
The statistical significance of the data obtained from the cytoxicity assays and TNF-t levels was calculated using a modified Wilcoxon signed-rank test (Conover & Iman, 1981 burden. IL-7-induced LAK activity was also found to be proportional to the E/T ratio (Figure 2 , as paradigmatically shown for one patient).
IL-2-induced LAK activity higher than activity of unstimulated PBLs was generated in 13 out of 14 patients and was higher than LAK activity generated by IL-7 in all patients (Figure 1) . The mean cytotoxicity of IL-2-generated LAK cells was 78% (± 24.6) against SK-Mel-37 and 73.5% (Worm et al., 1993 ) is depicted at an ET ratio of 20:1. Unstimulated PBLs ( = ) were grown in complete medium containing 10% fetal calf serum and were used as controls (P = 0.05). The mean percentage lysis and the standard deviation are given. All experiments were performed in quintuplicate and were repeated at least twice. I all patients were found to lyse autologous melanoma cells to a variable degree (Figure 3 and Table I , as shown for five patients). The mean cytotoxicity of LAK cells generated by IL-7 was 55.8% (± 25.6) and by IL-2 68.7% (± 21.7), at an E/T ratio of 20:1. Interestingly, IL-7-induced LAK activity in PBLs from two patients exceeded IL-2-induced LAK activity by 32% and 13% (patients K.U. and S.U. in Figure  3 ). LAK activity of IL-2-and IL-7-induced LAK cells directed against autologous melanoma cells was also found to be proportional to the EIT ratio (data not shown).
Comparison between allogeneic and autologous LAK activity derivedfrom melanoma patients To exclude intraindividual variations in LAK activity when blood samples were taken and processed at different times, PBLs from five patients were isolated, and the cytotoxicity of IL-7-and IL-2-induced LAK cells was measured simultaneously against allogeneic and autologous melanoma cells (Table I) . No consistent pattern of LAK activity against allogeneic and autologous melanoma cells could be found. In patient K.I., the IL-7-induced LAK activity against autologous melanoma cells was almost identical to the activity of unstimulated PBLs, and IL-2-induced autologous LAK activity was also in the lower range compared with other patients shown in Table I and Figure 3 . In contrast, 0-0-U, Ji allogeneic LAK activity generated by IL-2 was high in this particular patient.
IL-7-induced LAK cells produce less TNF-a than LAK cells generated by IL-2 Figure 4 shows the concentration of TNF-u in the supernatants of the LAK-cell cultures generated by IL-7 or IL-2 in comparison with unstimulated PBLs. The median of the concentration of TNF-a in the supernatants of IL-2-induced LAK cells was 325 pg ml-' (range 68-2,050 pg ml-') in contrast to 147 pgml-' (range 15-1,055pgml-') in the supernatants of IL-7-induced LAK-cell cultures (P<0.01). No differences between TNF-1 levels in supernatants of IL-7-induced PBLs was noted compared with levels of unstimulated PBLs (median ll9pgml-', range 15-392pg ml-'). No (1,000) (1,000)/IL-2 (10) (1,000)/IL-2 (1,000) (a) Lymphocyte proliferation (1,000 U ml') and suboptimal concentrations of IL-2 (10 U ml-') cooperate in their capacity to promote lymphocyte proliferation compared with IL-2 (10 U ml-') (P<0.05) ( Table Ila) . As can be seen in Table lIb , cytotoxicity increased dose dependently with IL-2 concentration. However, LAK activity of IL-2 (10 U ml-') was significant lower than the combination of suboptimal IL-2 (10 U ml-') and IL-7 (1,000 U ml') (P<0.05).
DEi IL-7 has recently been found to induce LAK activity in PBLs derived from healthy donors against a variety of target cells, including haematological cell lines (A erson et al., 1990; St6tter & Lotze, 1991; St6tter et al., 1991) and allogeneic melanoma cell lines (Schadendorf et al., 1994a) . In our previous experiments, IL-7-induced LAK cells from healthy donors lysed SK-Mel-37 and SK-Mel-23 at a mean percentage of 41% (± 12%) (Schadendorf et al., 1994a) . We have amplified these findings by analysing the IL-7-induced LAK activity of patients with melanoma against allogeneic and, more importantly, autologous melanoma cells. The mean cytoxicity of IL-7-induced LAK cells directed against SK-Mel-37 and SK-Mel-23 (36.5 ± 17.5%) is only slightly lower and not significantly different from LAK cells derived from healthy donors and patients with metastatic melanoma. It remains unclear whether the reduced allogeneic IL-7-induced LAK activity in three of 14 patients can be attributed to a general or specific immunosuppression or whether it reflects normal interindividual variations in the inducibility of LAK cells. Reduced natural killer (NK)-cell activity has been reported in patients with advanced cancer (Morikawa et al., 1989; Villa et al., 1991) . On the other hand, we found striking interindividual differences in the degree of IL-7-induced LAK cell-activity even among healthy volunteers (Schadendorf et al., 1994a) .
More important than alloreactive LAK activity of IL-7-induced LAK cells from patients with melanoma seems to be the fact that IL-7 enables PBLs to kill autologous melanoma cells. Bearing in mind that LAK activity induced by IL-7 acts in large part independently of IL-2 (St6tter et al., 1991a), this cytokine seems a possible alternative to IL-2 and a good candidate for future immunotherapy of patients with advanced melanoma. IL-7-induced LAK activity in PBLs from two patients even exceeded that of IL-2 by 32% and 13%. These data extend the findings of Jicha et al. (1992) , who showed a similar cytoxicity of IL-7-and IL-2-generated draining lymph node-derived lymphocytes against syngeneic autologous MCA tumour.
The effector cell phenotype of IL-7-induced LAK cells was studied by Naume et al. (1991) and shown to be of the CD56+CD3-phenotype. Furthermore, Smyth et al. (1991) demonstrated that large granular lymphocytes (LGLs) (mainly CD56+CD3-phenotype) stimulated by IL-7 had LAK activity and secreted IFN-r, although in lower quantities than IL-2.
Differences in LAK activity between allogeneic and autologous cells have been reported (Foa et al., 1990) . High alloreactive LAK activity coupled with low LAK activity directed against autologous melanoma cells may be related in part to clonal expansion of alloreactive MHC-restricted NK cells, as recently postulated (Moretta et al., 1992) . Differences in the responsiveness to IL-2 and IL-7 activation of NK cells could be another reason. However, other mechanisms, such as the induction of co-stimulatory signals, including adhesion molecules, as described recently (Altomonte et al., 1993; Piali et al., 1993; Poggi et al., 1993; Vyth-Dreese et al., 1993) , have to be considered. Such a mechanism might help to explain the high autologous cytotoxicity generated by IL-7 observed in 2/5 of our patients (K.I. and S.U.). Specific cytotoxic T lymphocytes (CTILs) are most likely not involved, since the precursor frequency for tumour-specific CTLs ranges around 1:20,000 and effective clonal proliferation of CTLs needs between 2 and 4 weeks (Coulie et al., 1992) .
The finding that IL-7-induced LAK cells produce less TNF-a than IL-2-induced LAK cells is in accordance with data from others who have shown a 50-fold lower amount of that cytoline in the supernatants of IL-7-stimulated immunomagnetically purified CD56+ lymphocytes (Naume et al., 1991) . Since TNF-a as well as IFN-r is thought to be involved in the pathogenesis of the capillary leakage syndrome during high-dose immunotherapy with IL-2 (Siegel & Puri, 1991) , lower in vivo induction of these cytokines during immunotherapy with IL-7 is likely to cause fewer side-effects than IL-2.
Taken together, our previous (Schadendorf et al., 1994a) (Schadendorf et al., 1994a) , lower induction of cytokines such as TNF-a upon IL-7 application may minimise severe side-effects that are commonly seen during high-dose immunotherapy with IL-2.
Our findings are encouraging for clinical pilot studies on patients with advanced melanoma using IL-7 either alone or in combination with 
